Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers

Metabolism: Clinical and Experimental

Volumn 56, Issue 4, 2007, Pages 559-564

  Takase, Hiroyuki ^a   Nakazawa, Ai ^b   Yamashita, Sumiyo ^b   Toriyama, Takayuki ^a   Sato, Koichi ^c   Ueda, Ryuzo ^b   Dohi, Yasuaki ^b  

^a Enshu General Hospital   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c Johoku Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; PIOGLITAZONE; VASCULAR CELL ADHESION MOLECULE 1; VOGLIBOSE;

AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; RECEPTORS, ANGIOTENSIN; THIAZOLIDINEDIONES; VASCULITIS;

EID: 33947303644     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.01.002     Document Type: Article

References (38)

1. Gress T.W., Nieto F.J., Shahar E., et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342 (2000) 905-912
2. Sowers J.R., and Bakris G.L. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med 342 (2000) 969-970
3. Davis T.M., Millns H., Stratton I.M., et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 159 (1999) 1097-1103
4. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
5. Goldstein L.B., Adams R., Becker K., et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 103 (2001) 163-182
6. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36 (2000) 646-661
7. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
8. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
9. Brasier A.R., Recinos A.R., and Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22 (2002) 1257-1266
10. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
11. Harrison D., Griendling K.K., Landmesser U., et al. Role of oxidative stress in atherosclerosis. Am J Cardiol 91 (2003) 7A-11A
12. Dohi Y., Ohashi M., Sugiyama M., et al. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 26 (2003) 691-697
13. Fliser D., Buchholz K., Haller H., and European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110 (2004) 1103-1107
14. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
15. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest 106 (2000) 467-472
16. Hung Y.J., Lin S.H., Pei D., et al. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein. Metabolism 55 (2006) 439-444
17. Barbier O., Torra I.P., Duguay Y., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22 (2002) 717-726
18. Verges B. Clinical interest of PPARs ligands. Diabetes Metab 30 (2004) 7-12
19. Sarafidis P.A., Lasaridis A.N., Nilsson P.M., et al. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 54 (2005) 1236-1242
20. Jackson S.M., Parhami F., Xi X.P., et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19 (1999) 2094-2104
21. Ricote M., Li A.C., Willson T.M., et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
22. Pasceri V., Wu H.D., Willerson J.T., et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101 (2000) 235-238
23. Hsueh W.A., Jackson S., and Law R.E. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24 (2001) 392-397
24. Satoh N., Ogawa Y., Usui T., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26 (2003) 2493-2499
25. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
26. Ridker P.M. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 92 Suppl (2003) 17K-22K
27. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
28. Nakamura T., Matsuda T., Kawagoe Y., et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 53 (2004) 1382-1386
29. Dormandy J.A., Charbonnel B., Eckland D.J., et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
30. Baron A.D. Postprandial hyperglycaemia and alpha-glucosidase inhibitors. Diabetes Res Clin Prac 40 Suppl (1998) S51-S55
31. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25 (2004) 10-16
32. Yamasaki Y., Katakami N., Hayaishi-Okano R., et al. Alpha-glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 67 (2005) 204-210
33. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
34. Rifai N., Tracy R.P., and Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45 (1999) 2136-2141
35. Willerson J.T., and Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 109 Suppl 1 (2004) II2-II10
36. Suwaidi J.A., Hamasaki S., Higano S.T., et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101 (2000) 948-954
37. Bugiardini R., Manfrini O., Pizzi C., et al. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 109 (2004) 2518-2523
38. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684